Axiom-4 to carry 1st FDA-approved cancer drug for space testing
Axiom-4 mission
will be carrying '
Rebecsinib
', the first cancer drug with active US FDA 'Investigational New Drug' (IND) status to be tested in microgravity, marking a significant milestone in space-based pharmaceutical research.
Axiom said the experimental cancer treatment, developed by Aspera Biomedicines, targets ADAR1, a gene responsible for cancer cloning and immune evasion. Unlike previous space missions that tested research compounds, Ax-4 will carry a drug already approved for clinical trials on Earth.
"We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," said Dr Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute and founder of Aspera Biomedicines. Rebecsinib underwent evaluation during Axiom-2 & 3 missions.
Microgravity provides unique advantages for cancer research, with tumours growing approximately twice as fast in space. Dr Jamieson noted a doubling in growth of mini-tumours within just 10 days, effectively mimicking aggressive cancer progression in patients and enabling researchers to obtain more reliable scientific results in shorter time frames.The mission aims to generate additional preclinical data for diverse tumour types using patient-derived tumour organoids. This accelerated testing environment allows researchers to identify better drug candidates with improved odds of success in patients, particularly those with faster disease progressions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Apollo, Siemens collaborate to advance liver healthcare with AI innovation
Apollo Hospitals and Siemens Healthineers on Wednesday announced a research collaboration founded on a shared ambition to advance innovations in artificial intelligence (AI) and imaging technologies, with the goal of improving lives. The research, spanning quantitative ultrasound imaging to AI-driven clinical solutions, aims to enhance liver disease management by improving patient care pathways and outcomes—from early detection and risk stratification to monitoring intervention and therapy response. The partnership combines technical and clinical expertise to develop innovative healthcare solutions for the growing burden of liver diseases in India, with a focus on early diagnosis, accurate detection, and precise monitoring to improve patient outcomes. As per Government of India guidelines, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), referred to as NAFLD in the report, is a growing cause of liver disease in India. Its prevalence ranges from 9 per cent to 32 per cent and is higher among individuals who are overweight, obese, or have diabetes. According to NFHS-4 (2015–2016), 18–20 per cent of adults are overweight or obese and 3–8 per cent have abnormal blood sugar levels. MASLD significantly increases cardiovascular risk, with heart disease being the leading cause of death. 'At Apollo, we believe that the future of healthcare lies at the intersection of clinical excellence and cutting-edge technology anchored in patient centricity. Our collaboration with Siemens Healthineers is a transformative step in using AI to redefine non-invasive diagnostics for liver disease. Due to diagnostic challenges and the evolving understanding of the disease, the true prevalence of MASLD may be underestimated. This poses a significant public health challenge, requiring increased awareness, early detection, and effective management strategies,' said Sangita Reddy, joint managing director, Apollo Hospitals. 'AI-driven disease progression models will play a pivotal role in the early detection of fibrosis, allowing timely interventions, cost-effective screening, and improved patient outcomes. These models will also facilitate precision population health strategies and clinical decision support across care settings. This partnership reflects Apollo's pioneering vision to embed intelligent systems across the clinical spectrum that enable faster, more accurate diagnoses and proactive patient management,' she added. 'Liver disease is a growing health concern in India. It's crucial to prioritise early diagnosis and prevention through advanced diagnostic tools, lifestyle changes, and increased awareness to reverse this trend. We believe that advanced technologies will aid timely and precise diagnosis, leading to better disease management and improved quality of life for patients. Our joint effort will help address the unmet needs in liver disease diagnosis and treatment, and we look forward to a fruitful partnership,' said Hariharan Subramanian, managing director, Siemens Healthcare. Following the 2024 memorandum of understanding, the Master Research Agreement (MRA) was formalised in March 2025, establishing a foundation for collaborative research in diagnostic and interventional ultrasound imaging. The signing ceremony for the MRA addendum was held on July 23, 2025, in Hyderabad, marking a significant milestone in this partnership.
Fibre2Fashion
an hour ago
- Fibre2Fashion
Godavari Biorefineries gets Chinese patent for cancer molecule
Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB), through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China's patent and trademark office for its novel anti-cancer molecule - HYDROXY-1,4-NAPHTHALENEDIONE. This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer. 'Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,' said Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. 'This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide.' Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its focus in translational research that addresses some of the world's most urgent health challenges. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Godavari Biorefineries' biotech arm, Sathgen Therapeutics, has secured a Chinese patent for its anti-cancer molecule Hydroxy-1,4-Naphthalenedione. The compound shows strong in vitro efficacy against cancer and cancer stem cells. GBL continues to expand globally, focusing on innovative cancer and antiviral therapies through advanced translational research. ALCHEMPro News Desk (HU)
NDTV
2 hours ago
- NDTV
A Daughter Of India Soon To Touch The Stars. ISRO, Government Determined
New Delhi: India's space odyssey is poised to take a historic leap forward, one that would include the country's daughters among its astronauts. In an exclusive conversation with Air Vice Marshal Anupam Agarwal, Assistant Chief of Air Staff (Medical) and a leading space medicine expert, the roadmap for India's inclusive future in space was laid out with clarity and conviction. India will soon get women astronauts as part of Gaganyaan. The Axiom-4 flight, often referred to as Mission Akash Ganga, has already made headlines with the successful return of Group Captain Shubhanshu Shukla from the International Space Station. But this is the beginning of an entire process, one that would include women, civilians, and people from all walks of life. Why No Women in the First Cohort The absence of women in the initial astronaut cohort has sparked questions and debate. Air Vice Marshal Agarwal addressed this directly, explaining the constraints faced during the selection process in 2019. "These are unprecedented situations," he said. "When you are building space systems from the ground up, there are many variables that are difficult to fathom at the beginning," he said. In 2019, the Indian Air Force had only male test pilots. Since the first mission required individuals with highly specialized skills to handle unknown and potentially dangerous scenarios, the selection was limited to test pilots. "A test pilot is someone you ask to fly an aircraft that's never flown before, he or she will do it at 1000 kilometres an hour, and land it safely," Air Vice Marshal Agarwal explained. "You need such a person when you're making a spacecraft for the first time. You're not sure about the systems inside it." This skill set, reflexes, adaptability, and the ability to remain calm under pressure, is critical. And in 2019, the pool of qualified candidates with these attributes consisted solely of men. "We didn't have a choice," Air Vice Marshal Agarwal said. "There were no female test pilots in the Indian Armed Forces at that time." Even today, while there are several women fighter pilots in the Indian Air Force, none have reached the seniority level to qualify as test pilots -- which has very stringent qualifying criteria. Global Indians The American space agency NASA has flown women of Indian origin to space like late Astronaut Kalpana Chawla and Astronaut Sunita Williams, but both were citizens of USA. A Future That Includes India's Daughters Despite these initial limitations, the future is bright and inclusive. Air Vice Marshal Agarwal confirmed that women will soon join the astronaut corps. "ISRO has been very particular that we need to be inclusive," he said. "And the Government of India has emphasized this as well. If I dare to look into the future, we should have women soon," he said. Speaking from the ramparts of the Red Fort on Independence Day in 2018, Prime Minister Narendra Modi had also asserted: "We have a dream. Our scientists have a dream. We have resolved... some of our young boys and girls will unfurl the Tricolour in space." This commitment to inclusion is not just symbolic - it reflects a broader expansion of India's vision for space exploration. Future astronauts may not necessarily be scientists or engineers. They could be civilians, educators, artists, or individuals from other professions, representing the full spectrum of Indian society. "India's daughter will go to space soon. This is the order of the Indian government. She will come," Air Vice Marshal said.
